Effect of Compound Lingdan Capsule on liver function and fibrosis degree in mice with liver fibrosis

Zhixin TU; Yan WANG; Jianjie HUANG; Qinglong JIN

doi:10.3969/j.issn.1001-5256.2023.04.010

Volume 39 Issue 4

Apr. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(4): 804-809

PDF( 4219 KB)

Effect of Compound Lingdan Capsule on liver function and fibrosis degree in mice with liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2023.04.010

Department of Hepatology, The First Hospital of Jilin University, Changchun 130000, China

Research funding:

National Natural Science Foundation of China (81270484)

More Information

Corresponding author: JIN Qinglong, jinql@jlu.edu.cn(ORCID: 0000-0002-4626-9828)
Received Date: 2022-09-07
Accepted Date: 2022-10-24
Published Date: 2023-04-20

Abstract

Abstract

Objective To investigate the effect of Compound Lingdan Capsule on serum biochemical parameters and liver fibrosis degree in a mouse model of liver fibrosis. Methods A total of 125 specific pathogen-free male C57BL/6 mice were randomly divided into normal control group with 5 mice, CCl₄ model group with 15 mice, low-, middle-, and high-dose CCl₄ groups (0.8, 1.6, and 3.2 mg·g^-1·d^-1) with 15 mice in each group, DDC model group with 15 mice, and low-, middle-, and high-dose DDC groups (0.8, 1.6, and 3.2 mg·g^-1·d^-1) with 15 mice in each group. After successful modeling, the mice in the administration groups were given Compound Lingdan Capsule suspension at the respective doses by gavage, and those in the normal control group and the model group were given an equal volume of normal saline by gavage, for 4 consecutive weeks. Blood samples were collected from the eyeballs, and serum was used to measure aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, and bilirubin. Liver tissue samples were collected at the same site of the right lobe of the liver for pathological observation, Sirius Red staining, α-SMA antibody staining, and COL1A1 antibody staining. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the Bonferroni method was used for further comparison between two groups. Results Compared with the model group, each dose group had significant reductions in the serum level of ALT and a significant increase in the serum level of albumin after the administration of Compound Lingdan Capsule (all P < 0.05), the levels of AST and bilirubin in the middle and high dose groups were lower (all P < 0.05), and the difference of each index in the high dose group was more significant than that in the low dose group (all P < 0.05). Each dose group had varying degrees of improvement in the pathological changes of the liver and a significant reduction in the number of Sirius Red staining-positive cells, as well as varying degrees of reduction in the protein expression of α-SMA and COL1A1. Conclusion Compound Lingdan Capsule can improve liver function and reduce liver fibrosis degree in mice with liver fibrosis.
- Liver Cirrhosis,
- Mice, Inbred C57BL,
- Compound Lingdan Capsule

FullText(HTML)

References(17)

References

[1]	FRIEDMAN SL. Liver fibrosis-from bench to bedside[J]. J Hepatol, 2003, 38(Suppl 1): S38-S53. DOI: 10.1016/s0168-8278(02)00429-4.
[2]	KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. DOI: 10.1038/s41575-020-00372-7.
[3]	WEISKIRCHEN R, WEISKIRCHEN S, TACKE F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts[J]. F1000Res, 2018, 7: F1000 Faculty Rev-921. DOI: 10.12688/f1000research.14841.1.
[4]	DU WT, REN WL, HU DD, et al. Research progress on reversible animal model of liver fibrosis[J/CD]. Chin J Liver Dis (Electronic Version), 2022, 14(3): 18-21. DOI: 10.3969/j.issn.1674-7380.2022.03.005. 杜文涛, 任万雷, 胡豆豆, 等. 肝纤维化可逆转动物模型研究进展[J/CD]. 中国肝脏病杂志(电子版), 2022, 14(3): 18-21. DOI: 10.3969/j.issn.1674-7380.2022.03.005.
[5]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis (2019)[J]. J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
[6]	Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007. 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
[7]	PAROLA M, PINZANI M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65: 37-55. DOI: 10.1016/j.mam.2018.09.002.
[8]	LAI M, AFDHAL NH. Liver fibrosis determination[J]. Gastroenterol Clin North Am, 2019, 48(2): 281-289. DOI: 10.1016/j.gtc.2019.02.002.
[9]	HAMMEL P, COUVELARD A, O'TOOLE D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct[J]. N Engl J Med, 2001, 344(6): 418-423. DOI: 10.1056/NEJM200102083440604.
[10]	ARTHUR MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C[J]. Gastroenterology, 2002, 122(5): 1525-1528. DOI: 10.1053/gast.2002.33367.
[11]	KWEON YO, GOODMAN ZD, DIENSTAG JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B[J]. J Hepatol, 2001, 35(6): 749-755. DOI: 10.1016/s0168-8278(01)00218-5.
[12]	DIXON JB, BHATHAL PS, HUGHES NR, et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss[J]. Hepatology, 2004, 39(6): 1647-1654. DOI: 10.1002/hep.20251.
[13]	CZAJA AJ, CARPENTER HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis[J]. J Hepatol, 2004, 40(4): 646-652. DOI: 10.1016/j.jhep.2004.01.009.
[14]	ZHANG Y, LYU WL. Visual analysis of traditional Chinese medicine in the treatment of hepatic fibrosis based on CiteSpace[J]. China Med Herald, 2022, 19(19): 129-132, 137. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202219026.htm 张亚, 吕文良. 基于CiteSpace中医药治疗肝纤维化的可视化分析[J]. 中国医药导报, 2022, 19(19): 129-132, 137. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202219026.htm
[15]	WANG HY, NIU JQ, ZHANG WY, et al. Experimental study on the anti-hepatic fibrosis effect of Compound Lingdan Capsule[J]. Chin Traditional Patent Med, 2014, 36(1): 168-171. DOI: 10.3969/j.issn.1001-1528.2014.01.042. 王化宇, 牛俊奇, 张炜煜, 等. 复方灵丹胶囊抗肝纤维化作用的实验研究[J]. 中成药, 2014, 36(1): 168-171. DOI: 10.3969/j.issn.1001-1528.2014.01.042.
[16]	FALLOWFIELD JA, MIZUNO M, KENDALL TJ, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis[J]. J Immunol, 2007, 178(8): 5288-5295. DOI: 10.4049/jimmunol.178.8.5288.
[17]	DOOLEY S, DELVOUX B, STRECKERT M, et al. Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells[J]. FEBS Lett, 2001, 502(1-2): 4-10. DOI: 10.1016/s0014-5793(01)02656-4.

Relative Articles

[1]	Peng ZHANG, Shihao ZHENG, Siyuan GOU, Jinchi XIE, Xianzhao YANG, Yongan YE. The mechanism of compound traditional Chinese medicine prescriptions in reversal of liver fibrosis and early liver cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1873-1879. doi: 10.12449/JCH240924
[2]	Yijing XIN, Yiyun CHEN, Hailin YANG, Yunhui ZHUO, Dingqi ZHANG, Fengfeng ZHOU. Effect of Xuanfuhua decoction on a mouse model of nonalcoholic steatohepatitis induced by high-fat, high-fructose, and high-cholesterol diet[J]. Journal of Clinical Hepatology, 2023, 39(6): 1340-1350. doi: 10.3969/j.issn.1001-5256.2023.06.014
[3]	Hao TANG, Yixiao YIN, Wei LIU, Yi FANG, Jun WANG, Yiyang HU, Jinghua PENG. Effects of Xuefu Zhuyu decoction and its extracts on a mouse model of nonalcoholic fatty liver disease induced by high-fat diet[J]. Journal of Clinical Hepatology, 2022, 38(12): 2728-2737. doi: 10.3969/j.issn.1001-5256.2022.12.010
[4]	Jing YANG, Suxin LI, Yuehui ZHANG, Luhao LI, Zhaochen LIU, Dongqi SHEN, Xiaowei DANG. Effect of metformin on liver fibrosis in a mouse model of Budd-Chiari syndrome[J]. Journal of Clinical Hepatology, 2022, 38(9): 2034-2039. doi: 10.3969/j.issn.1001-5256.2022.09.017
[5]	Tiantian GONG, Shaogang HUANG, Ruizhen SUN, Jingling SHEN, Qiuming LI, Lei LEI, Zhiyan SHAN. Effect of macrophages on the differentiation of mouse induced pluripotent stem cells into hepatic progenitor cells[J]. Journal of Clinical Hepatology, 2021, 37(4): 852-856. doi: 10.3969/j.issn.1001-5256.2021.04.025
[6]	Gerui ZHU, Jing WANG, Kai HUANG, Yuan PENG, Chenghai LIU, Yanyan TAO. A transcriptomic analysis of acute hepatotoxicity induced by aristolochic acid Ⅰ in mice[J]. Journal of Clinical Hepatology, 2021, 37(10): 2389-2394. doi: 10.3969/j.issn.1001-5256.2021.10.026
[7]	Xuling LIU, Guangyue YANG, Wei ZHANG, Tiantian SUN, Wenting MA, Liu WU, Dongying XUE, Cheng LIU, Le TAO. Therapeutic effect of Taohong Siwu decoction on a mouse model of carbon tetrachloride-induced liver fibrosis and its mechanism[J]. Journal of Clinical Hepatology, 2021, 37(11): 2563-2568. doi: 10.3969/j.issn.1001-5256.2021.11.016
[8]	Wang Yu, Lu: Jing, Liu ChengHai. Histological reversal after treatment of drug-induced cirrhosis with Yiqi Liangxue TCM combined with Fuzheng Huayu Capsule: A case report[J]. Journal of Clinical Hepatology, 2019, 35(11): 2542-2544. doi: 10.3969/j.issn.1001-5256.2019.11.030
[9]	Wang Hu, Cheng Yujia, Wang Li, Liao Yifeng, Cao Jiang. Interventional effect of mangiferin on carbon tetrachloride-induced hepatic fibrosis in mice[J]. Journal of Clinical Hepatology, 2019, 35(4): 808-812. doi: 10.3969/j.issn.1001-5256.2019.04.020
[10]	Zhang LiXia, Li Ying, Wang LiMing, Yan Xiang. Bone marrow mesenchymal stem cell transplantation via different approaches in treatment of liver cirrhosis in mice[J]. Journal of Clinical Hepatology, 2016, 32(10): 1906-1910. doi: 10.3969/j.issn.1001-5256.2016.10.016
[11]	Gao YuanZheng, Jia SuHua, Zhao LianFeng, Jiang Ying, Wang Yan. Clinical efficacy of entecavir combined with Xinganbao capsules in treatment of liver cirrhosis among patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(4): 314-316. doi: 10.3969/j.issn.1001-5256.2014.04.007
[12]	Zhu HuiJia, Hou YiJun, Yuan KaiZhen, Xu LanMan, Lin Zhuo, Chen YongPing. Inhibitory effect of Anfate on expression of TGFβ1 /Smad2 signaling pathway in treatment of hepatic fibrosis in mice[J]. Journal of Clinical Hepatology, 2014, 30(4): 335-339. doi: 10.3969/j.issn.1001-5256.2014.04.012
[13]	Yang Li, Feng AiDong, Zheng HaoJie, Dai ErHei. Effects of Ruangan Huajian granules on mRNA expression of MMP- 13 and TIMP- 1 in liver tissue among C57 mice with hepatic fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(4): 340-343. doi: 10.3969/j.issn.1001-5256.2014.04.013
[14]	Ye LiHong, Wang ChongKui, Yang Li, Gao HuiXia, Zhao ZhaoXia, Hou JunLiang, Dai ErHei. Effects of Ruangan Huajian granule on hepatic expression of α-SMA, TGFβ1, and COL-Ⅰ in C57 mice with experimental hepatic fibrosis [J]. Journal of Clinical Hepatology, 2012, 28(9): 685-688.
[15]	Wen Wei, Fan GongRen, Ren YongQiang, Han JuQiang, Hu XueLing, Yao Peng. Clinical efficacy of Adefovir dipivoxil combined with Fufang Biejia tablets in treating decompensated cirrhosis in hepatitis with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(3): 268-269+276.
[16]	Feng JianWen, Liu LiXin, Zhang HaiYan, Zhang QianQian. The effect and significance of exogenous IGFBPrP1 on liver and kidney tissue in mice[J]. Journal of Clinical Hepatology, 2011, 27(8): 827-832+836.
[17]	Ye LiHong, Wang ChongKui, Tian YueYang, Xu Yi, Zheng HaoJie, Shao ShiXiang, Dai ErHei. Effect of Ruangan Huajian granule on hepatic expression of PDGF - B in C57 mice with experimental hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1047-1050.
[18]	Lin Yan, Song ZhenYa, Fan YanPing, Wang HaiZhen, Yu YongFang, Wu MengJuan. The application and valuation of IRIS13 C-methacetin breath test in patients with cirrhosis.[J]. Journal of Clinical Hepatology, 2008, 24(2): 96-98.
[19]	Feng Jie, Tang ZhengHao, Zhang RongGui, Zang GuoQing, Yu YongSheng. The expression of C-fos and EGFR in human hepatocellular carcinoma and hepatic cirrhosis tissues.[J]. Journal of Clinical Hepatology, 2008, 24(3): 210-212.
[20]	Yin HeKun, Li QiXiang, Luo Dan. The clinical study of L-ornithine-L-aspartate combined with SNMC for hepatic encephalopathy of liver cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(4): 268-269.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (479) PDF downloads(48)

Effect of Compound Lingdan Capsule on liver function and fibrosis degree in mice with liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2023.04.010

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of Compound Lingdan Capsule on liver function and fibrosis degree in mice with liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2023.04.010

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content